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The autocrine and paracrine activation of the
renin–angiotensin system (RAS) within cells of the kidney
plays a role in the overall pathophysiology of the renal
disease due to diabetes. In this study, we focus on
components of the RAS in the podocyte as these cells are
important in the pathogenesis of glomerulosclerosis and
proteinuria. Immortalized mouse podocytes were exposed to
media containing normal glucose (NG) or high glucose (HG)
for in vitro studies. In vivo studies utilized kidney tissue
obtained from rats treated for 3 months with streptozotocin
to induce diabetes. Angiotensinogen (AGT) and the
angiotensin II (AII) type 1 receptor mRNA and protein were
significantly increased in the podocytes cultured under the
high glucose conditions. Both angiotensins I and II levels
were significantly higher in cell lysates and the conditioned
media of cells grown in high glucose. There were no
differences in renin activity, angiotensin-converting enzyme
level, or AII type 2 receptor level. Glomerular AGT and AII
type 1 receptor assessed by means of immunohistochemistry
were increased in diabetic rats compared with the control
rats. Other measured components of the RAS within the
glomeruli were not different. We suggest that increased AGT,
an attendant increase in AII and increased AII type 1 receptor
in podocytes experiencing diabetic conditions play an
important role in the pathogenesis of diabetic nephropathy.
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Diabetic nephropathy, the leading cause of end-stage renal
disease in the US,1 is characterized pathologically by cellular
hypertrophy and increased extracellular matrix accumulation
and clinically by proteinuria.2,3 The molecular and cellular
mechanisms responsible for these disease characteristics
remain incompletely resolved. Although the diabetic milieu
per se, hemodynamic changes, and local growth factors such
as angiotensin II (AII) are considered to be mediators in the
pathogenesis of diabetic nephropathy,4 the underlying path-
ways mediating these processes are not well understood.
Previous clinical and experimental studies in diabetic
nephropathy have demonstrated that blockade of the
renin–angiotensin system (RAS) by angiotensin-converting
enzyme (ACE) inhibitors or AII receptor blockers reduced
proteinuria and the progression of nephropathy that cannot
be explained merely by their antihypertensive effect.5–7 These
findings suggest that RAS blockade may have direct effects on
various renal cells. Among them, many investigators have
focused on podocytes because they not only serve as a
filtration barrier to protein but also play an important role in
the pathogenesis of glomerulosclerosis.8 We have previously
demonstrated that AII receptor blockers ameliorates high
glucose-induced podocytes hypertrophy by inhibiting p27Kip1
mRNA and protein expression.9 In addition, others have
observed that blocking the RAS restores reduced nephrin
levels and attenuates foot process broadening in diabetic
nephropathy.10,11 Taken together, it seems that the inhibition
of AII may have a direct beneficial effect on podocytes.
AII is the major effector molecule of the RAS. It is a
powerful direct vasoconstrictor, promotes vascular smooth
muscle contraction and induces systemic hypertension.12
Besides its hemodynamic effects, AII plays an important role
in the pathogenesis of various renal diseases, including
diabetic nephropathy. It mediates apoptosis and inflamma-
tion via the angiotensin II type 1 receptor (AT1R), directly
stimulates transforming growth factor-b1 production and
signaling pathways such as mitogen-activated protein kinase,
lipooxygenase, and phosphatidylinositol 3-kinase, and con-
tributes to the development and maintenance of renal
hypertrophy, matrix expansion, and glomerulosclerosis.13,14
In diabetes, intrarenal RAS is known to be activated in spite
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of low plasma renin activity.15 Recent studies have demon-
strated that local RAS is activated in mesangial cells16,17 and
proximal tubular cells13 by hyperglycemia and in podocytes
by mechanical strain.18 Moreover, we have also observed
previously an increase in AII levels in podocyte lysates as well
as in their conditioned culture media by high glucose.9
However, the mechanisms by which high glucose increases
AII in podocytes are not yet clear.
To clarify the precise mechanism of high glucose-induced
AII production, we investigated the changes of RAS
components, including angiotensinogen (AGT), renin, AI,
ACE, AII, AT1R, and AT2R in high glucose-stimulated
podocytes. High glucose-induced changes in AII production
were further determined with specific inhibitors of ACE,
chymase, or protein kinase C (PKC) to confirm the
underlying pathway involved. In addition, we examined the
changes of RAS components in diabetic glomeruli to verify
the results of the in vitro experiments.
RESULTS
Podocyte culture studies
AGT mRNA and protein expression. We first determined the
changes in AGT mRNA and protein expression in podocytes
under diabetic conditions. The AGT/18S mRNA ratio was
1.9-fold higher in podocytes exposed to high glucose (HG)
than in those exposed to normal glucose (NG), and this HG-
induced increment in AGT mRNA expression was amelio-
rated by 87.5 and 90.9% with the pretreatment of calphostin
C and GF 109203X, respectively (Figure 1). The expression of
AGT protein showed a similar pattern to its mRNA
expression (Figure 2). On the other hand, there was no
significant difference in AGT/18S mRNA ratio between the
NG and NGþM (mannitol) groups.
Renin activity. We next evaluated the changes in renin
activities in podocytes and their conditioned media by
measuring AI levels in the presence of excess exogenous AGT
(1 mM). AI levels from AGT-treated conditions were increased
about two- to six-fold compared with AI levels without AGT
exposure. In cell lysates, the increases in AI concentrations in
the presence of AGT from the baseline value were as follows:
4.9970.91 pg/mg protein in the NG group, 5.2470.83 pg/mg
protein in the NGþM group, and 5.5670.64 pg/mg protein
in the HG group (P40.05). In the conditioned media, the
results were similar to those of cell lysates (D increases in AI
levels were NG, 2.8670.14 pg/ml; NGþM, 2.8270.35 pg/ml;
and HG, 2.9970.23 pg/ml, P40.05). PKC inhibitors had no
effect on the changes in AI concentrations in the presence of
excess exogenous AGT (Figure 3).
AI levels. AI levels were significantly higher in HG-treated
cell lysates compared with NG cell lysates (HG,
1.8470.45 pg/ml; NG, 0.8570.16 pg/mg protein, Po0.05)
and in the HG-conditioned media (HG, 2.6070.68 pg/ml;
NG, 0.8870.23 pg/ml, Po0.01), and PKC inhibitors nearly
normalized these HG-induced increases in AI concentrations
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Figure 1 | AGT mRNA expression in podocytes exposed to NG,
NGþM, or HG medium with or without PKC inhibitor, 107 M
calphostin C (CC) or 106 M GF 109203X (GFX) (N¼ 5). The
AGT/18S mRNA ratio was 1.9-fold higher in podocytes exposed to HG
than in those exposed to NG, and this HG-induced increment in AGT
mRNA expression was ameliorated by 87.5 and 90.9% with the
pretreatment of calphostin C and GF 109203X, respectively. On the
other hand, there was no significant difference in AGT/18S mRNA
ratio between the NG and NGþM groups. *Po0.05 vs NG, #Po0.05
vs HG.
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Figure 2 | Western blot of AGT in podocytes exposed to NG,
NGþM, or HG medium with or without PKC inhibitor, 107 M
calphostin C (CC) or 106 M GF 109203X (GFX) (representative of
five blots). AGT protein expression was significantly higher in
podocytes exposed to HG than in those exposed to NG. PKC
inhibitors nearly normalized the increases in AGT protein expression,
whereas mannitol had no effect on AGT protein expression.
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Figure 3 | Renin activities in podocytes exposed to NG, NGþM, or
HG medium with or without PKC inhibitor, 107 M calphostin C
(CC) or 106 M GF 109203X (GFX), and in their conditioned media
(N¼ 5). Renin activities were determined by measuring AI levels in
the presence of excess exogenous AGT (1 mM). The increases in AI
concentrations in the presence of AGT from the baseline value were
similar between the NG- and HG-stimulated cell lysates and between
their conditioned media. Mannitol or PKC inhibitors had no effect on
the changes in AI concentrations in the presence of excess
exogenous AGT.
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in cell lysates and in the conditioned media. On the other
hand, there were no significant differences in AI levels in cell
lysates or in the media between the NG and NGþM groups
(Figure 4).
ACE mRNA and protein expression, and ACE levels. The
ACE/18S mRNA ratio was not statistically different between
the NG and HG-treated cells (data not shown). As seen in
Figure 5, there was also no difference in ACE protein
expression among the groups. ACE levels determined by
enzyme-linked immunosorbent assay (ELISA) revealed that
ACE levels did not change in podocytes by HG (NG,
2.8770.42 pg/mg protein; HG, 2.9270.37 pg/mg protein).
Mannitol and PKC inhibitors had no effect on the ACE
mRNA and protein expression, and ACE levels.
AII levels. AII levels were significantly higher in HG-
treated cell lysates (0.3170.04 pg/mg protein) and in
HG-conditioned media (2.5470.33 pg/ml) compared with
NG-treated cells (0.1870.02 pg/mg protein, Po0.05) and
conditioned media (1.1370.12 pg/ml, Po0.01) (Figure 6a
and b). Captopril, chymostatin, calphostin C, and GF
109203X inhibited these HG-induced increments in AII
concentrations in cell lysates by 53.8, 69.2, 88.5, and 96.2%,
respectively, and in HG-conditioned media by 75.0, 82.1,
96.6, and 89.4%, respectively. Captopril and chymostatin also
reduced AII levels in NG cells and NG-conditioned media,
but did not reach statistical significance (data not shown).
Conversely, there was no significant difference in AII
concentrations between the NG and NGþM treatment
groups.
ATR mRNA and protein expression. The AT1R/18S mRNA
ratio in podocytes exposed to HG was 288% higher than in
NG-treated cells (Po0.005) (Figure 7). Western blot analysis
further supported the real-time polymerase chain reaction
results (Figure 8). Desitometric measurement revealed a
1.7-fold increase in AT1R protein expression in HG-treated
podocytes compared with NG cells. PKC inhibitors, calphos-
tin C, and GF 109203X, nearly normalized the increases in
AT1R mRNA and protein expression, whereas mannitol had
no effect on AT1R expression. In contrast, there were no
differences in AT2R mRNA and protein expression among
the groups.
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Figure 4 | AI levels in podocytes exposed to NG, NGþM, or HG
medium with or without PKC inhibitor, 107 M calphostin C (CC)
or 106 M GF 109203X (GFX), and in their conditioned media
(N¼ 5). AI concentrations were significantly higher in HG-treated cell
lysates and in the HG-conditioned media compared with
corresponding NG groups, and PKC inhibitors nearly normalized
these HG-induced increases in AI concentrations in cell lysates and in
the conditioned media. On the other hand, there were no significant
differences in AI levels in cell lysates or in the media between the NG
and NGþM groups. *Po0.05 vs NG, **Po0.01 vs NG, #Po0.05 vs HG.
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Figure 5 | A representative Western blot of ACE with podocytes
exposed to NG, NGþM, or HG medium with or without PKC
inhibitor, 107 M calphostin C (CC) or 106 M GF 109203X (GFX)
(N¼ 5). There was no significant difference in the ACE protein
expression among the groups.
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Figure 6 | AII levels in podocytes (a) exposed to NG, NGþM, or
HG medium with or without ACE inhibitor (104 M captopril,
CAPRIL), chymase inhibitor (104 M chymostatin, CHYMO), or PKC
inhibitor (107 M calphostin C, CC or 106 M GF 109203X, GFX),
and (b) in their conditioned media (N¼ 5). AII levels were
significantly higher in HG-treated cell lysates and in HG-conditioned
media compared with NG cells and conditioned media. Captopril,
chymostatin, calphostin C, and GF 109203X inhibited these
HG-induced increments in AII concentrations in cell lysates by
53.8, 69.2, 88.5, and 96.2%, respectively, and in HG-conditioned
media by 75.0, 82.1, 96.6, and 89.4%, respectively. On the other hand,
mannitol had no effect on AII levels in cell lysates and in conditioned
media. *Po0.05 vs NG, #Po0.05 vs HG, **Po0.01 vs NG.
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Animal studies
Animal data. Body weight increased in both control (C)
and diabetes mellitus (DM) groups throughout the 3-months
study period, but increased more in the former (51074 g)
than in the latter (26673 g) (Po0.01). The ratio of kidney
weight to body weight at the time of killing was significantly
higher in DM (1.6470.11%) than in C rats (0.5670.05%)
(Po0.01). Compared with the C (0.4070.06 mg/day), 24-h
urinary albumin excretion was significantly higher in the DM
group (1.9970.22 mg/day, Po0.05) (Table 1).
Intraglomerular AGT, ACE, AT1R, and AT2R mRNA and protein
expression. The changes in mRNA and protein expression of
the RAS components in DM glomeruli were similar to those
in high glucose-stimulated podocytes. The mRNA expression
of AGT and AT1R were increased in DM glomeruli by 63.1
and 81.3%, respectively, compared with C glomeruli
(Po0.05) (Figure 9). Western blot analysis also revealed
significant increases in AGT and AT1R protein expression in
DM glomeruli (Figure 10). The positive-stained cells within
glomeruli by immunohistochemistry were podocytes and
mesangial cells, with a clear predominance in the former. The
semiquantitative staining scores for glomerular AGT and
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Figure 7 | AT1R mRNA expression in podocytes exposed to NG,
NGþM, or HG medium with or without PKC inhibitor, 107 M
calphostin C (CC) or 106 M GF 109203X (GFX) (N¼ 5). The
AT1R/18S mRNA ratio in podocytes exposed to HG was 288% higher
than in NG-treated cells, and this HG-induced AT1R mRNA expression
was ameliorated by PKC inhibitors. On the other hand, there was no
significant difference in AT1R/18S mRNA ratio between the NG and
NGþM groups. *Po0.005 vs NG, #Po0.01 vs HG.
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Figure 8 | Western blot of AT1R and AT2R in podocytes exposed
to NG, NGþM, or HG medium with or without PKC inhibitor,
107 M calphostin C (CC) or 106 M GF 109203X (GFX)
(representative of five blots). C3H/10T1/2 cell lysate and Hep G2
cell lysate were loaded in the same gel as positive control for AT1R
and AT2R, respectively (POS). AT1R protein expression was
significantly higher in podocytes exposed to HG than in those
exposed to NG. Densitometric quantitation revealed that there was a
1.7-fold increase in AT1R protein expression in HG-treated podocytes
compared with NG cells. PKC inhibitors nearly normalized the
increases in AT1R protein expression, whereas mannitol had no effect
on AT1R protein expression. In contrast, there was no significant
difference in the AT2R protein expression among the groups.
Table 1 | Body weight, kidney weight, and urinary albumin
excretion of the rats
Parameters C DM
Body weight (g) 51074 26673a
Kidney weight/body weight (%) 0.5670.05 1.6470.11a
Blood glucose (mg/dl) 112.178.1 495.5711.2a
Urinary albumin excretion (mg/day) 0.4070.06 1.9970.22b
aPo0.01 vs C.
bPo0.05 vs C.
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Figure 9 | Glomerular AGT, ACE, AT1R, and AT2R mRNA
expression in control and DM rats. The mRNA expression of AGT
and AT1R were increased in DM glomeruli by 63.1 and 81.3%,
respectively, compared with C glomeruli, whereas ACE and AT2R
mRNA expression were not different between the two groups.
*Po0.05 vs control.
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Figure 10 | Western blot of AGT, ACE, AT1R, and AT2R in control
and DM glomeruli (representative of six blots). There were
significant increases in glomerular AGT and AT1R protein expression
in DM vs C rats, whereas ACE and AT2R protein expression of the two
groups were comparable.
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AT1R were significantly higher in DM (AGT, 59.379.1;
AT1R, 71.2710.2) than in C rats (AGT, 21.573.7; AT1R,
28.775.3) (Po0.05) (Figure 11). On the other hand, there
were no differences in ACE and AT2R mRNA and protein
expression between C and DM glomeruli.
DISCUSSION
In this study, we show for the first time that AII levels are
increased concurrently with ATIR mRNA and protein
expressions in podocytes exposed to high glucose and PKC
pathway is involved in these changes. In addition, high
glucose-induced AII generation is attributed to an increase in
AGT expression which results in an increase in the AII
substrate, rather than more conversion of AGT to AI or
increased conversion of AI to AII. The results of these in vitro
experiments were further verified by the in vivo findings.
Recently, studies have focused on the role of podocytes in
the pathophysiology of proteinuria in various glomerular
diseases, including diabetic nephropathy. It has been reported
that proteinuria is associated with decreased podocyte
numbers and/or densities and alterations in glomerular
filtration barrier-associated molecules.19,20 Glomerular po-
docyte numbers are known to decrease in type 1 and 2
diabetic patients, even in diabetes of short duration.21,22 A
recent study has also demonstrated a strong inverse
correlation between the changes in podocyte numbers and
urinary albumin excretion rates in diabetic patients.23
Consistent with the observed loss of podocytes, podocytes
were more detectable in the urine of diabetic patients with
proteinuria.24 Furthermore, the expression of nephrin, a key
podoctye-specific molecule, is decreased in human and
experimental diabetic nephropathy.25,26 However, both the
loss of podocytes and the reduction of nephrin expression are
inhibited by RAS blockade, suggesting that AII plays an
important role in the pathogenesis of diabetic nephropathy,
especially in the development of proteinuria.
AII, an octapeptide, is predominantly converted from a
decapeptide AI that is synthesized from AGT by renin. On
the other hand, the formation of active AII from inactive AI
is mediated by ACE and non-ACE enzymes. Under
physiologic conditions, ACE is known to be the most
important enzyme in the generation of AII.27 In this study,
high glucose had no effects on ACE expression and levels in
podocytes. These results were in accordance with previous
studies with high glucose-stimulated mesangial cells16 and
freshly isolated diabetic glomeruli.28 However, several
investigators have suggested that a non-ACE pathway may
play a role in the formation of local AII. Singh et al.16,28
raised the possibility of the existence of an ACE-related
carboxypeptidase other than ACE1 that could be inhibited by
an ACE inhibitor in mesangial cells and glomeruli. Among
non-ACE enzymes, chymase is the best known enzyme to be
involved in the conversion of AI to AII. A study using
immunohistochemistry showed chymase upregulation in
diabetic kidney, especially in mesangial cells and vascular
smooth muscle cells. However, chymase expression has not
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Figure 11 | Immunohistochemical staining for (a and b) AGT, (c and d) ACE, (e and f) AT1R, (g and h) AT2R, (i and j) b-actin, and
(k and l) synaptopodin in (a, c, e, g, i, and k) C and (b, d, f, h, j, and l) DM at 3 months after streptozotocin injection. The positive-stained
cells within glomeruli were podocytes and mesangial cells, with a clear predominance in the former. There were significant increases in
glomerular AGT and AT1R protein expression in DM vs C rats (arrowhead), whereas ACE and AT2R protein expression were not different
between C and DM glomeruli. On the other hand, the staining intensity of glomerular b-actin and synaptopodin in C and DM rats were
comparable (original magnification  400).
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been detected in the podocytes even in diabetic patients
with hypertension, in whom the chymase staining was
extremely strong.29
In this study, we demonstrate that even though renin
activity and ACE levels and expression do not change under
diabetic conditions, AGT expression is significantly increased
in high glucose-stimulated podocytes and in podocytes of
diabetic glomeruli. Similar to our results, the increase in AGT
expression by high glucose has also been demonstrated in
proximal tubular cells,30 mesangial cells,16,17 and peritoneal
mesothelial cells.31 Taken together, these findings suggest that
the increase of AII generation in podocytes by high glucose is
primarily due to an increase in AGT, serving as more
substrate for AII, rather than more conversion of AGT to AI
or increased conversion of AI to AII. In addition, our results,
that pretreatment with ACE inhibitor or chymase inhibitor
ameliorates the increase of AII levels in high glucose-
stimulated podocytes and their conditioned media, also
implies the involvement of both ACE and non-ACE pathways
in high glucose-induced AII production in podocytes.
AII exerts biological effects through its interaction with
the G-protein-coupled AII receptors on cell surface. Based on
the availability of nonpeptide receptor ligands, AII receptors
are classified into AT1R and AT2R groups. In vivo and in vitro
studies have revealed that podocytes express both AT1R and
AT2R. Differentiated podocytes predominantly express AT1R
(about 75%), with a lesser amount of AT2R (about 25%).32,33
AT1R is more important in mediating most of the
physiologic actions of AII. The role of AT1R was emphasized
in a recent study with transgenic rats that had overexpression
of human ATIR in podocytes.34 These rats developed
albuminuira and showed structural changes in the glomer-
ulus, including pseudocysts formation, foot process efface-
ment, and local detachments, followed by progression to
focal segmental glomerulosclerosis. In addition, AT1R has
been reported to mediate the processes of enhanced DNA
synthesis,32 depolarization,35 and reorganization of F-actin
fibers and redistribution of zonula occludens-1 of podocytes
induced by AII,36 as well as mechanical strain-induced
apoptosis of podocytes,18 and macrophage infiltration in
experimental diabetic nephropathy.37 In contrast, AT2R
receptors are highly expressed in fetal tissues, but their
expression is markedly downregulated after birth.38 The
physiologic role of AT2R in the kidney is not well
understood, but has been suggested to counteract the role
of AT1R, including vasodilation, natriuresis, and inhibition
of cell proliferation.39 Moreover, both AT1R and AT2R are
known to mediate the AII-induced production of cyclic
adenosine monophosphate.32 In this study, we demonstrate
increased AT1R expression, both in vitro and in vivo, with no
changes in AT2R expression, a result which is in agreement
with a previous study on mechanically stretched podocytes.
The documented changes of AT1R expression patterns under
diabetic conditions have not been consistent. In peritoneal
mesothelial cells31 and vascular smooth muscle cells,40 AT1R
mRNA and protein expression were upregulated by high
glucose treatments, but downregulated in high glucose-
stimulated mesangial cells41 and streptozotocin-induced
diabetic glomeruli.42 Although the reasons for this divergence
in AT1R expression are unclear, differences in cell type, DM
duration, and the duration and concentration of high glucose
stimulation may all contribute to these findings.
When a terminal effector is increased, the expression of its
receptor is generally downregulated by a negative feedback
mechanism. However, this general trend was not applicable
to podocytes stimulated by high glucose or by mechanical
strain. In both conditions, AII levels were increased with the
concomitant increase in AT1R expression. In addition, we
found that AGT and AT1R expression were also increased in
podocytes of diabetic glomeruli. As hyperglycemia per se and
increased glomerular capillary pressure are considered
mediators in the pathogenesis of diabetic nephropathy,
upregulated AT1R along with increased local AII in
podocytes may potentiate the deleterious effect of AII.
Meanwhile, recent clinical studies have shown that dual
blockade with an ACE inhibitor and an AT1R blocker is more
effective than monotherapy in reducing proteinuria and
slowing the progression of diabetic nephropathy.43,44 We
think that the results of this study provide strong evidences
for the benefit of dual blockade in the treatment of diabetic
nephropathy.
Numerous studies have revealed that PKC is activated in
diabetic conditions, in vivo and in vitro.45 In addition, the
PKC pathway is a key signal pathway associated with the
activation of transforming growth factor b1 and fibronectin
synthesis, which are important in the pathogenesis of diabetic
nephropathy.46 In this study, increased AII levels and AT1R
expression were ameliorated by the PKC inhibitor, suggesting
that inhibition of the PKC pathway may mitigate the
deleterious effects of increased local AII under diabetic
conditions.
In conclusion, high glucose induced AGT mRNA and
protein expression in cultured podocytes via PKC pathway
and resulted in increased AI and AII production. In addition,
despite higher AII concentrations, AT1R mRNA and protein
expression were increased in high glucose-stimulated podo-
cytes. Increased AGT and AT1R expression were also
demonstrated in podocytes of diabetic glomeruli. Even
though mesangial and endothelial cells as well as podocytes
were included in isolated glomeruli, we surmised that these
increases might be due to the changes in podocytes
considering the results of immunohistochemistry. These
findings suggest that the increase in both AGT expression,
resulting in increased AII production, and AT1R expression
in podocytes under diabetic conditions may play an
important role in the pathogenesis of diabetic nephropathy.
MATERIALS AND METHODS
Podocyte culture
Conditionally immortalized mouse podocytes were kindly provided
by Dr Peter Mundel (Albert Einstein College of Medicine,
Bronx, NY, USA) and were cultured as described previously.47
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Differentiated podocytes, grown for 14 days at 371C, were serum
restricted for 24 h, and the medium was changed to serum-free
Roswell Park Memorial Institute medium containing NG (5.6 mM),
HG (30 mM), or NGþM (24.4 mM) with or without 6-h pretreat-
ment of ACE inhibitor (104 M captopril; Sigma Chemical Co., St
Louis, MO, USA), chymase inhibitor (104 M chymostatin, Sigma
Chemical Co.), or PKC inhibitor (107 M calphostin C or 106 M GF
109203X; Calbiochem, San Diego, CA, USA). To clarify the role of
PKC in the activation of local RAS, two different kinds of PKC
inhibitors, calphostin C and GF 109203X, which are known to react
with the regulatory and catalytic domain of PKC,48,49 respectively,
were used. The concentrations of captopril, chymostatin, calphostin
C, and GF 109203X used in this study were determined based on the
preliminary experiments. At 24 h after the media change, cells were
harvested for either RNA or protein, and the conditioned culture
media were collected for the measurement of renin activity and the
levels of AI and AII.
Animals
All animal studies were conducted using approved protocols. Sixteen
male Sprague–Dawley rats, weighing 220–250 g were studied. Eight
were injected with diluent (control, C) and eight with 65 mg/kg
streptozotocin intraperitoneally (DM). Blood glucose levels were
measured 3 days after the streptozotocin injection to confirm the
development of diabetes. The rats were given free access to water
and standard laboratory chow during the 3-month study period. All
rats were killed after 3 months.
Body weights were checked monthly, and kidney weights were
measured at the time of killing. Serum glucose and 24-h urinary
albumin were measured monthly. Blood glucose was measured by
glucometer, and 24-h urinary albumin excretion was determined by
ELISA (Nephrat II, Exocell Inc., Philadelphia, PA, USA).
Total RNA isolation and reverse transcription
Glomeruli were isolated by sieving. Purity of the glomerular
preparation was greater than 98% as determined by light
microscopy. Total RNA was extracted from sieved glomeruli and
podocytes, and 2 mg of total RNA extracted were reverse transcribed
as described previously.9
Real-time PCR
The primers and the PCR conditions used in the experiments are
summarized in Table 2. Using the ABI PRISM 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA), the
PCR was performed with a total volume of 20 ml in each well,
containing 10 ml of SYBR Green PCR Master Mix (Applied
Biosystems), 5 ml of cDNA corresponding to 25 ng of RNA, and
5 pmol sense and antisense primers. Primer concentrations were
determined by preliminary experiments that analyzed the optimal
concentrations of each primer. The PCR conditions were as follows:
40–45 cycles, denaturation at 951C for 45 s, annealing at the
corresponding temperature for 45 s, and extension at 721C for
1 min. Initial heating at 951C for 9 min and a final extension at 721C
for 7 min were performed for all PCRs. Each sample was run in
triplicate in separate tubes to permit quantification of the gene
normalized to the 18S gene. After real-time PCR, the temperature
was increased from 60 to 951C at a rate of 21C/min to construct a
melting curve. A control without cDNA was run in parallel with each
assay. The cDNA content of each specimen was determined using a
comparative CT method with 2
DDCT . The results are given as relative
expression normalized to the 18S gene and expressed in arbitrary
units. Signals from C glomeruli and NG podocytes were assigned a
relative value of 1.0. In pilot experiments, PCR products run on
agarose gels revealed a single band.
Western blot analysis
Sieved glomeruli and podocytes harvested from plates were lysed in
sodium dodecyl sulfate sample buffer (2% sodium dodecyl sulfate,
10 mM Tris-HCl, pH 6.8, 10% (vol/vol) glycerol). Aliquots of 50mg
of protein were treated with Laemmli sample buffer, heated at 1001C
for 5 min, and electrophoresed with 50mg/lane in an 8–12%
acrylamide denaturing sodium dodecyl sulfate-polyacrylamide gel.
Proteins were then transferred to a Hybond-enhanced chemilumi-
nescence membrane (Amersham Life Science Inc., Arlington
Heights, IL, USA) using a Hoeffer semidry blotting apparatus
(Hoeffer Instruments, San Francisco, CA, USA), and the membrane
was then incubated in blocking buffer A (1 phosphate-buffered
saline, 0.1% Tween 20, and 8% non-fat milk) for 1 h at room
temperature, followed by an overnight incubation at 41C with a
1:1000 dilution of monoclonal anti-AGT antibody (Research
Diagnostics Inc., Concord, MA, USA), polyclonal anti-ACE anti-
body, monoclonal anti-AT1R antibody, monoclonal anti-AT2R
antibody, or polyclonal b-actin antibody (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA). The membrane was then washed once
for 15 min and twice for 5 min in 1 phosphate-buffered saline with
0.1% Tween 20. Next, the membrane was incubated in buffer A
containing a 1:1000 dilution of horseradish peroxidase-linked goat
anti-rabbit immunoglobulin G (Amersham Life Science Inc.). The
washes were repeated, and the membrane was developed with a
chemiluminescent agent (enhanced chemiluminescence; Amersham
Life Science Inc.).
Measurement of renin activity
Renin activities in cell lysates and their conditioned culture
media were measured as the formation of AI in the presence of
excess substrate, AGT. Samples were incubated with porcine AGT
(1mM) at 371C for 1 h, followed by the measurement of AI levels
using a commercial ELISA kit (Peninsula Laboratories, Belmont,
CA, USA).
Table 2 | Sequences of primers
Sequence (50-30)
18S Mouse, rat Sense AGTCCCTGCCCTTTGTACACA
Antisense GATCCGAGGGCCTCACTAAAC
AGT Mouse Sense CGGTGTCGGAGAACCATTCT
Antisense CGCGCTACAAGGCGTGAT
Rat Sense CAGCGTCAGAGAGCTATC
Antisense CTTGCTGGAAGGAGTGA
ACE Mouse Sense GGAGTACTTCCAACCGGTCA
Antisense GCCTTGGCTTCATCAGTCTC
Rat Sense GGAGTACTTCCAACCAGTAA
Antisense GCCTTGGCTTCATCAGTCTC
AT1R Mouse Sense TCGCTACCTGGCCATTGTC
Antisense TGACTTTGGCCACCAGCAT
Rat Sense CCGCTACCTGGCCATCGTC
Antisense TGACTTTGGCCACCAGCAT
AT2R Mouse Sense CCTTCTTGGATGCTCTGACC
Antisense GCGGTTTCCAACAAAACAAT
Rat Sense CCTTCTTGGATGCTCTGACC
Antisense GCGGTTTCCAACGAAACAAT
ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AT1R, angiotensin II
type 1 receptor; AT2R, angiotensin II type 2 receptor.
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ELISA for AI, AII, and ACE
AI and AII levels were determined in podocyte lysates and in their
conditioned culture media, whereas ACE levels were measured only
in cell lysates. After seeding podocytes on 100 mm dishes and serum
restriction for 24 h, the medium was changed as described above.
Twenty-four hours later, the media were collected and the cells were
washed with ice-cold phosphate-buffered saline, scraped from the
dishes in the presence of extraction buffer (20 mM Tris-HCl, pH 7.4,
10 mM ethylenediaminetetraacetic acid, 5 mM ethylenegylcol tetra-
acetate, 5 mM b-mercaptoethanol, 50 mg/ml phenylmethyl sulfonyl
fluoride, 10 mM benzamidine, and 0.1 mg/ml aprotinin), and
homogenized. Cell lysates and conditioned media were centrifuged
at 15 000 r.p.m. for 10 min at 41C, and the supernatants were
collected.
AI and AII levels were determined using a commercial ELISA
kit (Peninsula Laboratories) by the avidin–streptavidin method,
as described previously.50 Briefly, samples or standards were
incubated with anti-AI or AII antibody and biotinylated AI or AII
(B-AI or B-AII) in 96-well plates coated with Staphylococcus
aureus protein A. After incubation, the unbound B-AI or B-AII
was removed by washing, and the bound B-AI or B-AII
was determined by reaction of streptavidin-horseradish peroxide
in the wells using 3,30,5,50-tetramethyl benzidine and H2O2
as a substrate. The reaction was terminated with 2 N HCl, and the
color intensity in each well was read at 450 nm using an ELISA
microtiter plate reader. The AI or AII amount in each well was
calculated from the standard curve and normalized with the total
protein content, which had been previously determined by a
modified Lowry method.
ACE levels were also determined using a commercially available
ELISA kit (Chemicon International Inc., Tamecula, CA, USA). ACE
activity was measured by a fluorometric assay using a fluorescence
O-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline. Briefly, 100ml
of samples or standards were applied to the 96-well plates in triplicate
and incubated at 371C for 2 h. After four washes with wash buffer,
anti-ACE:horseradish peroxide was added to the respective wells and
incubated at 371C for 1 h. Samples were washed and incubated with
100ml 3,30,5,50-tetramethyle benzadne substrate at room temperature
for 30 min. Absorbances at 450 nm were detected and ACE
concentrations were calculated from the standard curve and normal-
ized with total protein content.
Immunohistochemistry
Slices of kidney for immunohistochemical staining were fixed in
10% neutral-buffered formalin, processed in the standard manner,
and 5 mm sections of paraffin-embedded tissues were utilized. Slides
were deparaffinized, hydrated in ethyl alcohol, and washed in tap
water. Antigen retrieval was carried out in 10 mM sodium citrate
buffer for 20 min using a Black and Decker vegetable steamer.
Primary antibodies for AGT, ACE, AT1R, or AT2R were diluted in
appropriate concentrations with 2% casein in bovine serum albumin
and were applied for overnight incubation at 41C. We also used
polyclonal b-actin and monoclonal synaptopodin (podocyte
protein) antibody (Research Diagnostic Inc.) for control staining.
After washing, a secondary antibody was added for 20 min, the slides
were washed and incubated with a tertiary rabbit–peroxidase-
conjugated antiperoxidase complex for 20 min. Diaminobenzidine
was added for 2 min and the slides were counterstained with
hematoxylin. A semiquantitative score for measuring intensity of
staining within glomeruli was determined by examining 30
glomeruli in each section and by digital image analysis (MetaMorph
version 4.6r5, Universal Imaging Corp., Downingtown, PA, USA) as
described previously.51
Statistical analysis
All values are expressed as the mean7s.e.m. Statistical analysis was
performed using the statistical package SPSS for Windows Ver. 11.0
(SPSS Inc., Chicago, IL, USA). Results were analyzed using the
analysis of variance or Student’s t-test for comparisons. Significant
differences by the analysis of variance were further confirmed by the
Student’s t-test using the Bonferroni correction. Po0.05 was
considered to be statistically significant.
ACKNOWLEDGMENTS
This work was supported in part by the BK21 (Brain Korea 21) Project
for Medical Sciences, Yonsei University, Korea.
REFERENCES
1. US Renal Data System. USRDS 2004 annual data report. Am J Kidney Dis
2005; 45: 8–280.
2. Adler S. Structure–function relationships associated with extracellular
matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 1994; 5:
1165–1172.
3. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal
disease. With emphasis on the stage of incipient diabetic nephropathy.
Diabetes 1983; 32: 64–78.
4. Leehey DJ, Singh AK, Alavi N et al. Role of angiotensin II in diabetic
nephropathy. Kidney Int 2000; 77: S93–S98.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy.
N Engl J Med 1993; 329: 1456–1462.
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med 2001; 345: 861–869.
7. Gross ML, El-Shakmak A, Szabo A et al. ACE-inhibitors but not endothelin
receptor blockers prevent podocyte loss in early diabetic nephropathy.
Diabetologia 2003; 46: 856–868.
8. Barisoni L, Mundel P. Podocyte biology and the emerging understanding
of podocyte diseases. Am J Nephrol 2003; 23: 353–360.
9. Xu ZG, Yoo TH, Ryu DR et al. Angiotensin II receptor blocker inhibits
p27Kip1 expression in glucose-stimulated podocytes and in diabetic
glomeruli. Kidney Int 2005; 67: 944–952.
10. Langham RG, Kelly DJ, Cox AJ et al. Proteinuria and the expression of the
podocyte slit diaphragm protein, nephrin, in diabetic nephropathy:
effects of angiotensin converting enzyme inhibition. Diabetologia 2002;
45: 1572–1576.
11. Misfud SA, Allen TJ, Bertram JF et al. Podocyte foot process broadening in
experimental diabetic nephropathy: amelioration with renin–angiotensin
blockade. Diabetologia 2001; 44: 878–882.
12. Wolf G, Butzmann U, Wenzel UO. The renin–angiotensin system and
progression of renal disease: from hemodynamics to cell biology.
Nephron Physiol 2003; 93: P3–P13.
13. Zhang SL, To C, Chen X et al. Essential role(s) of the intrarenal
renin–angiotensin system in transforming growth factor-beta1 gene
expression and induction of hypertrophy of rat kidney proximal tubular
cells in high glucose. J Am Soc Nephrol 2002; 13: 302–312.
14. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy:
emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29:
153–163.
15. Price DA, Porter LE, Gordon M et al. The paradox of the low-renin state in
diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382–2391.
16. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased
angiotensin II levels in glomerular mesangial cells cultured in high
glucose. J Am Soc Nephrol 2003; 14: 873–880.
17. Vidotti DB, Casarini DE, Cristovam PC et al. High glucose concentration
stimulates intracellular renin activity and angiotensin II generation in rat
mesangial cells. Am J Physiol Renal Physiol 2004; 286: F1039–F1045.
18. Durvasula RV, Petermann AT, Hiromura K et al. Activation of a local tissue
angiotensin system in podocytes by mechanical strain. Kidney Int 2004;
65: 30–39.
19. Bains R, Furness PN, Critchley DR. A quantitative immunofluorescence
study of glomerular cell adhesion proteins in proteinuric states. J Pathol
1997; 183: 272–280.
1026 Kidney International (2007) 71, 1019–1027
o r i g i n a l a r t i c l e T-H Yoo et al.: Local RAS in podocytes under diabetic conditions
20. Xu ZG, Ryu DR, Yoo TH et al. P-cadherin is decreased in diabetic glomeruli
and in glucose-stimulated podocytes in vivo and in vitro studies. Nephrol
Dial Transplant 2005; 20: 524–531.
21. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in
normal subjects and in type 1 diabetic patients. Kidney Int 2001; 59:
2104–2113.
22. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and
progressive glomerular injury in type 2 diabetes. J Clin Invest 1979; 99:
342–348.
23. White KE, Bilous RW, Marshall SM et al. Podocyte number in normotensive
type 1 diabetic patients with albuminuria. Diabetes 2002; 51: 3083–3089.
24. Nakamura T, Ushiyama C, Suzuki S et al. Urinary excretion of podocytes in
patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15:
1379–1383.
25. Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in
human diabetic nephropathy: evidence for a distinct role for glycated
albumin and angiotensin II. Diabetes 2003; 52: 1023–1030.
26. Bonnet F, Cooper ME, Kawachi H et al. Irbesartan normalises the
deficiency in glomerular nephrin expression in a model of diabetes and
hypertension. Diabetologia 2001; 44: 874–877.
27. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and
treatment. Am J Kidney Dis 2000; 36: S4–S9.
28. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II
formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal
Physiol 2005; 288: F1183–F1190.
29. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in
diabetic nephropathy: implications for an alternative pathway of
angiotensin II-mediated diabetic renal and vascular disease. J Am Soc
Nephrol 2003; 14: 1738–1747.
30. Wang TT, Wu XH, Zhang SL, Chan JS. Effect of glucose on the expression
of the angiotensinogen gene in opossum kidney cells. Kidney Int 1998;
53: 312–319.
31. Noh H, Ha H, Yu MR et al. Angiotensin II mediates high glucose-induced
TGF-beta1 and fibronectin upregulation in HPMC through reactive
oxygen species. Perit Dial Int 2005; 25: 38–47.
32. Wang L, Flannery PJ, Spurney RF. Characterization of angiotensin
II-receptor subtypes in podocytes. J Lab Clin Med 2003; 142: 313–321.
33. Liebau MC, Lang D, Bohm J et al. Functional expression of the renin
angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006;
27: F710–F719.
34. Hoffmann S, Podlich D, Hahnel B et al. Angiotensin II type 1 receptor
overexpression in podocytes induces glomerulosclerosis in transgenic
rats. J Am Soc Nephrol 2004; 15: 1475–1487.
35. Gloy J, Henger A, Fischer KG et al. Angiotensin II modulates cellular
functions of podocytes. Kidney Int 1998; 67: S168–S170.
36. Macconi D, Abbate M, Morigi M et al. Permselective dysfunction of
podocyte–podocyte contact upon angiotensin II unravels the molecular
target for renoprotective intervention. Am J Pathol 2006; 168: 1073–1085.
37. Lee FT, Cao Z, Long DM et al. Interactions between angiotensin II and
NF-kappaB-dependent pathways in modulating macrophage infiltration
in experimental diabetic nephropathy. J Am Soc Nephrol 2004; 15:
2139–2151.
38. Perlegas D, Xie H, Sinha S et al. The angiotensin type-2 receptor regulates
smooth muscle growth and force generation in late fetal mouse
development. Am J Physiol Heart Circ Physiol 2004; 288: H96–H102.
39. Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol
Hypertens 2005; 14: 67–71.
40. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1
receptor expression and potentiate ANG II-induced proliferation in VSM
cells. Am J Physiol Heart Circ Physiol 2003; 284: H846–H852.
41. Amiri F, Garcia R. Regulation of angiotensin II receptors and PKC isoforms
by glucose in rat mesangial cells. Am J Physiol 1999; 276: F691–F699.
42. Ballermann BJ, Skorecki KL, Brenner BM. Reduced glomerular angiotensin
II receptor density in early untreated diabetes mellitus in the rat. Am J
Physiol 1984; 247: F110–F116.
43. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE
inhibition and angiotensin II receptor blockade in type I diabetic patients
with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992–999.
44. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of
adding angiotensin II receptor blocker to maximal recommended doses
of ACE inhibitor in diabetic nephropathy: a randomized double-blind
crossover trial. Diabetes Care 2003; 26: 2268–2274.
45. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from
streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest
1989; 83: 1167–1175.
46. Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the
mediation of increased fibronectin accumulation by mesangial cells
grown in high glucose medium. Diabetes 1993; 42: 118–126.
47. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the
cytoskeleton and cell contacts induce process formation during
differentiation of conditionally immortalized mouse podocyte cell lines.
Exp Cell Res 1997; 236: 248–258.
48. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C
(UCN-1028C), a novel microbial compound, is a highly potent and specific
inhibitor of protein kinase C. Biochem Biophys Res Commun 1989; 159:
548–553.
49. Toullec D, Pianetti P, Coste H et al. The bisindolylmaleimide GF 109203X is
a potent and selective inhibitor of protein kinase C. J Biol Chem 1991;
266: 15771–15781.
50. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II
in glucose-induced inhibition of mesangial matrix degradation. Diabetes
1999; 48: 2066–2073.
51. Kang SW, Natarajan R, Shahed A et al. Role of 12-lipoxygenase in the
stimulation of p38 mitogen-activated protein kinase and collagen
alpha5(IV) in experimental diabetic nephropathy and in
glucose-stimulated podocytes. J Am Soc Nephrol 2003; 14: 3178–3187.
Kidney International (2007) 71, 1019–1027 1027
T-H Yoo et al.: Local RAS in podocytes under diabetic conditions o r i g i n a l a r t i c l e
